68ga-nodaga-e(c[rgdyk])2
Small moleculeexperimentalImaging agent
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02970786)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- 68ga-nodaga-e(c[rgdyk])2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03505346 | Phase 2 | Jan 1, 2019 | University of Copenhagen |
| NCT03655977 | N/A | Sep 1, 2018 | University of Copenhagen |
| NCT03445884 | Phase 2 | Feb 20, 2018 | University of Copenhagen |
| NCT03393689 | Phase 2 | Jan 2, 2018 | University of Copenhagen |
| NCT03271281 | Phase 2 | Nov 20, 2017 | University of Copenhagen |
| NCT02970786 | Phase 1 | Nov 1, 2016 | University of Copenhagen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 6 | 6 | 3 | 2016 |
1 organizations
Page 1 / 1